Prolactin screening programs in patients receiving long-term treatment (>6 months) with these types of antipsychotics may be necessary, even in the absence of clinical symptoms relating to hyperprolactinemia, in order to identify those with the highest risk of developing medication-induced osteopenia and osteoporosis. The gene discussed is PRL; the disease is osteoporosis.